Clinical Trial

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Name: Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection — clinical trial record (NCT03859128)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JUPITER 04

Active, Not Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.

Trial Details

NCT Number	NCT03859128
Lead Sponsor	Shanghai Junshi Bioscience Co., Ltd.
Conditions	Hepatocellular Carcinoma
Enrollment	427 participants
Start Date	2019-03-05
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10